Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.


PURPOSE We conducted a phase II study to evaluate the efficacy and safety of the combination of irinotecan and paclitaxel in patients with advanced stage non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Patients were eligible if they had histologically confirmed chemotherapy naïve stage IV NSCLC or stage IIIB disease that was not suitable for… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.